Journal français d’ophtalmologie (2018) 41, 397—401 Disponible en ligne sur ScienceDirect www.sciencedirect.com ORIGINAL ARTICLE Real study: Re-treatment evaluated on visual acuity for Lucentis ® in neovascular AMD Real study : retraitement par Lucentis ® dans la DMLA neovasculaire évalué sur l’acuité visuelle D. Bellocq a,∗,b , F. De Bats a,b,c , M. Rabilloud d,e,f,g , L. Kodjikian a,b a Department of Ophthalmology, Croix-Rousse University Hospital, Hospices Civils de Lyon, University of Lyon I, 69004 Lyon, France b CNRS UMR 5510 Mateis, 69621 Villeurbanne, France c Polevision, Clinique du Val d’Ouest, 69130 Ecully, France d Université de Lyon, 69000 Lyon, France e Université Lyon 1, 69622 Villeurbanne, France f CNRS, UMR5558, laboratoire de biométrie et biologie évolutive, 69622 Villeurbanne, France g Service de Biostatistique, Hospices Civils de Lyon, 162, avenue Lacassagne, 69003 Lyon, France Received 28 June 2017; accepted 20 October 2017 Available online 17 May 2018 KEYWORDS Best corrected visual acuity; Neovascular AMD Summary Purpose. — To assess the value of a monthly injection of Lucentis ® until stable visual acuity (VA) is obtained for three consecutive months without exudation in patients with neovascular age macular degeneration (AMD). Methods. — Prospective, single-center, non-controlled trial including naïve AMD patients with neovascularization. An assessment of VA and a spectral domain optical coherence tomogra- phy (SD-OCT) were performed at baseline and every month. Monthly injections of Lucentis ® were performed over three months. The monthly injections were then continued until three consecutive stable VA results were obtained with no signs of exudation. ∗ Corresponding author. Service d’ophtalmologie, hôpital de la Croix-Rousse, 103, Grande rue de la Croix Rousse, 69317 Lyon cedex 04, France. E-mail address: davidbellocq@hotmail.com (D. Bellocq). https://doi.org/10.1016/j.jfo.2017.10.014 0181-5512/© 2018 Elsevier Masson SAS. All rights reserved.